Healthcare Business

clinical trials

CTI BioPharma Stumbles Over Full Clinical Hold

CTI BioPharma Corp. (NASDAQ: CTIC) has practically become a penny stock overnight following an update from its Investigational New Drug (IND) application for pacritinib. The update basically states that the ...
Read Full Story »
IPO

Proteostasis Therapeutics Closes in on IPO

Proteostasis Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). This company expects to price its 3.85 million ...
Read Full Story »
hospital entrance

Humana Outlook Raises Share Price After Earnings

Humana Inc. (NYSE: HUM) reported fourth-quarter and full-year 2015 results before markets opened Wednesday. For the quarter, the health care company posted adjusted diluted earnings per share (EPS) of $1.45 ...
Read Full Story »
Medicine pills

Short Sellers Increase Bets in Major Pharma

The short interest data have been released for the January 29 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
biotech word cloud

Major Biotech Short Interest Continues to Be Mixed

The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
IPO

Corvus Pharma Prepares for IPO

Corvus Pharmaceuticals has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No pricing details were given in the filing. ...
Read Full Story »
FDA_logo

Adaptimmune Receives Breakthrough Designation From FDA

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy designation for the company’s affinity enhanced T-cell therapy targeting NY-ESO in synovial ...
Read Full Story »
Red Cross

Cerus Announces New Partnership With Red Cross

Cerus Corp. (NASDAQ: CERS) led the bulls in Tuesday’s trading session on news of a new partnership with one of the biggest charities in the world. The company announced that ...
Read Full Story »
Pfizer

Why Merrill Lynch Sees Big Upside in Pfizer (and Even More With Allergan)

Pfizer Inc. (NYSE: PFE) offers a compelling valuation, an attractive dividend yield and good pipeline optionality. This is in part due to its merger with Allergan PLC (NYSE: AGN), which ...
Read Full Story »
automatic inspection machine

Regeneron Falls on Missed Earnings

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its fourth-quarter financial results before the markets opened on Tuesday. The company had $2.83 in earnings per share (EPS) on $1.10 billion in revenue, ...
Read Full Story »
health care

What to Expect From Centene Earnings

Health insurance provider Centene Corp. (NYSE: CNC) is scheduled to report fourth-quarter earnings on Tuesday before markets open. The company is expected to report earnings per share (EPS) of $0.86 ...
Read Full Story »
ThinkstockPhotos-481735362

Is BioCryst Reaching Crush Depth?

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is getting crushed after announcing results from OPuS-2 for the treatment of hereditary angioedema (HAE) attacks. Unfortunately, the company said that this treatment failed to ...
Read Full Story »
Prescription drugs

4 Big Dividend Pharmaceutical Stocks to Buy That Are Very Cheap Now

If you ever want to look for value in a sector in the stock market, then when you see Congress calling in some of the top companies to scold them ...
Read Full Story »
Medicine pills

How Analysts View Pfizer and Merck After Earnings

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) released their most recent earnings reports last week. As a result, analysts weighed in on both of these pharmaceutical ...
Read Full Story »
automatic inspection machine

How Analysts Value Gilead Now After Earnings

Gilead Sciences Inc. (NASDAQ: GILD) reported fourth-quarter financial results on Tuesday. As a result, analysts weighed in on this biotech giant and in what direction it might go next. The ...
Read Full Story »